CoChat

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: )-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study. METHODS: -mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in the tyrosine kinase domain (cohort 1), those with tumors harboring a mutation in the tyrosine kinase domain previously treated with a HER2-directed antibody-drug conjugate (cohort 5), and those with tumors harboring a non-tyrosine kinase domain mutation (cohort 3). In cohort 1, patients were initially randomly assigned to receive zongertinib at a dose of 120 mg or 240 mg once daily. Patients in cohorts 5 and 3 initially received 240 mg daily. After an interim analysis of data from cohort 1, subsequently recruited patients across all cohorts received zongertinib at a dose of 120 mg. The primary end point was an objective response assessed by blinded independent central review (cohorts 1 and 5) or by investigator review (cohort 3). Secondary end points included the duration of response and progression-free survival. RESULTS: In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0.001 against a ≤30% benchmark) had a confirmed objective response; the median duration of response was 14.1 months (95% CI, 6.9 to not evaluable), and the median progression-free survival was 12.4 months (95% CI, 8.2 to not evaluable). Grade 3 or higher drug-related adverse events occurred in 13 patients (17%). In cohort 5 (31 patients), 48% of the patients (95% CI, 32 to 65) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 1 patient (3%). In cohort 3 (20 patients), 30% of the patients (95% CI, 15 to 52) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 5 patients (25%). Across all three cohorts, no cases of drug-related interstitial lung disease occurred. CONCLUSIONS: -mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2503704

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 25 references

Cited by

See all 153

Metadata

Authors
Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H.-Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., & Zugazagoitia, J.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • The Netherlands Cancer Institute (NL)
  • Samsung Medical Center (KR)
  • Université de Versailles Saint-Quentin-en-Yvelines (FR)
  • Leiden University Medical Center (NL)
  • Université Paris-Saclay (FR)
  • Guangdong Academy of Medical Sciences (CN)
  • Yonsei University (KR)
  • National Cancer Center Hospital (JP)
  • NYU Langone Health (US)
  • Zhengzhou University (CN)
  • National Cancer Center Hospital East (JP)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim Pharma, Biberach an der Riss, Germany
  • Hospital Universitario 12 De Octubre (ES)
Venue
New England Journal of Medicine
Published
2025-06-19
Volume
392
Issue
23
Pages
2321-2333
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4409870405
Cited by
118
References
25
Citations by year
2026: 84 · 2025: 34
FWCI
77.02
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (publishedVersion)
  • HAL (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
zongertinib, HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, previously treated patients, tyrosine kinase domain mutations, objective response rate, progression-free survival, duration of response, drug-related adverse events, oral tyrosine kinase inhibitor
MeSH terms
Trastuzumab, Progression-Free Survival, Tyrosine Kinase Inhibitors, Adult, Aged, Aged, 80 and over, Camptothecin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2503704
The paper
Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H.-Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., & Zugazagoitia, J. (2025). Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2503704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.